Search by Drug Name or NDC
NDC 42806-0715-05 Benzonatate 200 mg/1 Details
Benzonatate 200 mg/1
Benzonatate is a ORAL CAPSULE in the HUMAN PRESCRIPTION DRUG category. It is labeled and distributed by Epic Pharma LLC. The primary component is BENZONATATE.
MedlinePlus Drug Summary
Benzonatate is used to relieve cough. Benzonatate is in a class of medications called antitussives (cough suppressants). It works by reducing the cough reflex in the lungs and air passages.
Related Packages: 42806-0715-05Last Updated: 11/30/2022
MedLinePlus Full Drug Details: Benzonatate
Product Information
| NDC | 42806-0715 |
|---|---|
| Product ID | 42806-715_9b35e9d5-7d72-4f51-a245-ad2467ab40e9 |
| Associated GPIs | 43102010000110 |
| GCN Sequence Number | 044168 |
| GCN Sequence Number Description | benzonatate CAPSULE 200 MG ORAL |
| HIC3 | H6C |
| HIC3 Description | ANTITUSSIVES, NON-OPIOID |
| GCN | 93007 |
| HICL Sequence Number | 001929 |
| HICL Sequence Number Description | BENZONATATE |
| Brand/Generic | Generic |
| Proprietary Name | Benzonatate |
| Proprietary Name Suffix | n/a |
| Non-Proprietary Name | Benzonatate |
| Product Type | HUMAN PRESCRIPTION DRUG |
| Dosage Form | CAPSULE |
| Route | ORAL |
| Active Ingredient Strength | 200 |
| Active Ingredient Units | mg/1 |
| Substance Name | BENZONATATE |
| Labeler Name | Epic Pharma LLC |
| Pharmaceutical Class | Decreased Tracheobronchial Stretch Receptor Activity [PE], Non-narcotic Antitussive [EPC] |
| DEA Schedule | n/a |
| Marketing Category | ANDA |
| Application Number | ANDA206948 |
| Listing Certified Through | 2024-12-31 |
Package
Package Images
NDC 42806-0715-05 (42806071505)
| NDC Package Code | 42806-715-05 |
|---|---|
| Billing NDC | 42806071505 |
| Package | 500 CAPSULE in 1 BOTTLE (42806-715-05) |
| Marketing Start Date | 2018-12-21 |
| NDC Exclude Flag | N |
| Pricing Information | |
| Price Per Unit | 0.12028 |
| Pricing Unit | EA |
| Effective Date | 2024-02-21 |
| NDC Description | BENZONATATE 200 MG CAPSULE |
| Pharmacy Type Indicator | C/I |
| OTC | N |
| Explanation Code | 1 |
| Classification for Rate Setting | G |
| As of Date | 2024-02-21 |
Standard Product Labeling (SPL)/Prescribing Information SPL 9b35e9d5-7d72-4f51-a245-ad2467ab40e9 Details
DESCRIPTION
Benzonatate capsules, USP, a non-narcotic oral antitussive agent, is 2, 5, 8, 11, 14, 17, 20, 23, 26- onaoxaoctacosan-28-ylp-(butylamino) benzoate; with a molecular weight of 603.7.
Each benzonatate capsules, USP for oral administration contains 100 mg or 200 mg benzonatate, USP. In addition, each capsule contains the following inactive ingredients: D&C Yellow #10, gelatin, glycerin, lecithin, light mineral oil, propylene glycol, purified water, shellac glaze, titanium dioxide, and white edible ink.
CLINICAL PHARMACOLOGY
Benzonatate capsules act peripherally by anesthetizing the stretch receptors located in the respiratory passages, lungs, and pleura by dampening their activity and thereby reducing the cough reflex at its source. It begins to act within 15 to 20 minutes and its effect lasts for 3 to 8 hours. Benzonatate capsules have no inhibitory effect on the respiratory center in recommended dosage.
WARNINGS
Hypersensitivity
Severe hypersensitivity reactions (including bronchospasm, laryngospasm and cardiovascular collapse) have been reported which are possibly related to local anesthesia from sucking or chewing the capsule instead of swallowing it. Severe reactions have required intervention with vasopressor agents and supportive measures.
Psychiatric Effects
Isolated instances of bizarre behavior, including mental confusion and visual hallucinations, have also been reported in patients taking Benzonatate capsules in combination with other prescribed drugs.
Accidental Ingestion and Death in Children
Keep benzonatate capsules out of reach of children. Accidental ingestion of benzonatate capsules resulting in death has been reported in children below age 10. Signs and symptoms of overdose have been reported within 15-20 minutes and death has been reported within one hour of ingestion. If accidental ingestion occurs, seek medical attention immediately (see OVERDOSAGE).
PRECAUTIONS
Benzonatate is chemically related to anesthetic agents of the para-amino-benzoic acid class (e.g. procaine; tetracaine) and has been associated with adverse CNS effects possibly related to a prior sensitivity to related agents or interaction with concomitant medication.
Information for Patients:
Swallow benzonatate capsules whole. Do not break, chew, dissolve, cut, or crush benzonatate capsules. Release of benzonatate from the capsule in the mouth can produce a temporary local anesthesia of the oral mucosa and choking could occur. If numbness or tingling of the tongue, mouth, throat, or face occurs, refrain from oral ingestion of food or liquids until the numbness has resolved. If the symptoms worsen or persist, seek medical attention.
Keep benzonatate capsules out of reach of children. Accidental ingestion resulting in death has been reported in children. Signs and symptoms of overdose have been reported within 15-20 minutes and death has been reported within one hour of ingestion. Signs and symptoms may include restlessness, tremors, convulsions, coma and cardiac arrest. If accidental ingestion occurs, seek medical attention immediately.
Overdosage resulting in death may occur in adults.
Do not exceed a single dose of 200 mg and a total daily dosage of 600 mg. If you miss a dose of benzonatate capsules, skip that dose and take the next dose at the next scheduled time. Do not take 2 doses of benzonatate capsules at one time.
Usage in Pregnancy
PREGNANCY CATEGORY C
Animal reproduction studies have not been conducted with benzonatate capsules. It is also not known whether benzonatate capsules can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. Benzonatate capsules should be given to a pregnant woman only if clearly needed.
Nursing Mothers
It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk caution should be exercised when benzonatate capsules are administered to a nursing woman.
ADVERSE REACTIONS
Potential Adverse Reactions to benzonatate capsules may include:
Hypersensitivity reactions including bronchospasm, laryngospasm, cardiovascular collapse possibly related to local anesthesia from chewing or sucking the capsule.
CNS
sedation; headache; dizziness; mental confusion; visual hallucinations.
GI
constipation; nausea; GI upset.
Dermatologic
pruritus; skin eruptions.
Other
nasal congestion; sensation of burning in the eyes; vague “chilly” sensation; numbness of the chest; hypersensitivity.
Deliberate or accidental overdose has resulted in death, particularly in children.
OVERDOSAGE
Intentional and unintentional overdose may result in death, particularly in children.
The drug is chemically related to tetracaine and other topical anesthetics and shares various aspects of their pharmacology and toxicology. Drugs of this type are generally well absorbed after ingestion.
Signs and Symptoms
The signs and symptoms of overdose of benzonatate capsules have been reported within 15-20 minutes. If capsules are chewed or dissolved in the mouth, oropharyngeal anesthesia will develop rapidly, which may cause choking and airway compromise.
CNS stimulation may cause restlessness and tremors which may proceed to clonic convulsions followed by profound CNS depression. Convulsions, coma, cerebral edema and cardiac arrest leading to death have been reported within 1 hour of ingestion.
Treatment
In case of overdose, seek medical attention immediately. Evacuate gastric contents and administer copious amounts of activated charcoal slurry. Even in the conscious patient, cough and gag reflexes may be so depressed as to necessitate special attention to protection against aspiration of gastric contents and orally administered materials. Convulsions should be treated with a short-acting barbiturate given intravenously and carefully titrated for the smallest effective dosage. Intensive support of respiration and cardiovascular-renal function is an essential feature of the treatment of severe intoxication from overdosage.
Do not use CNS stimulants.
DOSAGE AND ADMINISTRATION
Adults and Children over 10 years of age: Usual dose is one 100 mg or 200 mg capsule three times a day as needed for cough. If necessary to control cough, up to 600 mg daily in three divided doses may be given. Benzonatate capsules should be swallowed whole. Benzonatate capsules are not to be broken, chewed, dissolved, cut or crushed.
HOW SUPPLIED
Benzonatate Capsules USP, 100 mg are clear yellow, oval-shaped softgel capsules imprinted with “PC14” and are supplied as follows:
NDC 42806-714-01 in bottle of 100 capsules
NDC 42806-714-05 in bottle of 500 capsules
Benzonatate Capsules USP, 200 mg are clear yellow, oval-shaped softgel capsules imprinted with “PC15” and are supplied as follows:
NDC 42806-715-01 in bottle of 100 capsules
NDC 42806-715-05 in bottle of 500 capsules
Store at 20˚ to 25˚ C (68˚ to 77˚ F) [see USP Controlled Room Temperature].
PROTECT FROM LIGHT
Dispense in tight (USP), child-resistant containers.
Rx Only
Manufactured by:
Humanwell PuraCap Pharmaceutical
Wuhan, Hubei 430206, China
Distributed by:
Epic Pharma, LLC
Laurelton, NY 11413
Rev. 10-2018-00
PI-EBEN-00
INGREDIENTS AND APPEARANCE
| BENZONATATE
benzonatate capsule |
||||||||||||||||||||||
|
||||||||||||||||||||||
|
||||||||||||||||||||||
|
||||||||||||||||||||||
|
||||||||||||||||||||||
|
||||||||||||||||||||||
|
||||||||||||||||||||||
| BENZONATATE
benzonatate capsule |
||||||||||||||||||||||
|
||||||||||||||||||||||
|
||||||||||||||||||||||
|
||||||||||||||||||||||
|
||||||||||||||||||||||
|
||||||||||||||||||||||
|
||||||||||||||||||||||
| Labeler - Epic Pharma LLC (827915443) |
| Registrant - PURACAP PHARMACEUTICAL LLC (962106329) |
| Establishment | |||
| Name | Address | ID/FEI | Business Operations |
|---|---|---|---|
| Humanwell PuraCap Pharmaceuticals (Wuhan) Co., Ltd | 421293287 | MANUFACTURE(42806-714, 42806-715) | |